Navigation Links
Vasogen to Conduct Year-end 2007 Conference Call
Date:1/11/2008

s associated with the development and progression of cardiovascular and neurodegenerative disorders. The Company's lead product, the Celacade(TM) System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is being marketed in the EU by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage clinical development for the treatment of chronic heart failure in the United States. Vasogen is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.

Certain statements contained in this press release, the upcoming conference call and webcast, or elsewhere in our public documents constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to advance the development of Celacade(TM) or VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size, and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capi
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
2. Vasogen Provides an Update on ACCLAIM-II Preparations
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Announces Third Quarter 2007 Results
5. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
6. Hybrid semiconductors show zero thermal expansion; Could lead to hardier electronics
7. Katie Lee Joel to Conduct Free, Hands-On, Holiday Cooking Demonstration for Local Patients With Chronic Kidney Disease
8. NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Emerging Pharmaceutical Company
9. CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
10. Doping technique brings nanomechanical devices into the semiconductor world
11. IBM and Imago find a crucial difficulty in semiconductor device scaling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015  Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... that address unmet medical needs in the areas of ... be presenting preclinical data from three of its biodefense ... and Technology Conference on May 12-14, 2015 to be ... Convention Plaza, St. Louis MO ...
(Date:5/4/2015)... WASHINGTON , May 4, 2015   ... announced updated interim data from Tocagen,s ongoing investigational ... Satellite Symposium of the American Association of Neurological ... Tumors, held May 1-2, 2015, in ... the company held a meeting with FDA and ...
(Date:5/4/2015)... 04, 2015 Marianjoy Rehabilitation ... with arm and hand impairments by acquiring the ... Oakbrook Terrace network site. , Secured through grant ... a highly-regarded treatment option for patients with upper ... Marianjoy becomes one of just four Illinois providers ...
(Date:5/1/2015)... MINNEAPOLIS, MN , May 1, 2015 /PRNewswire/ - ... company producing sustainable chemicals, today announced that it has priced ... common stock at a price of $9.00 per share, ... option to purchase up to an additional 585,000 shares ... Company will be $35.1 million.  The offering is expected to ...
Breaking Biology Technology:Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 2Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 3Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 4Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 5Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 6Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 7Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 8Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 9Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 10Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 11Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO 12Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3
... has released a new medical imaging product for ... reading capabilities of radiologists. , ,According to Merge, the ... make possible simultaneous display and reading of images on ... which vendor's acquisition device is used to secure the ...
... Wis. - GE Healthcare has signed ... Excellence in Breast Cancer Imaging within the University ... ,With funding from GE Healthcare, a $17 billion unit ... designed to advance and commercialize research and technology to ...
... - CIOs must know something that Alan Greenspan doesn't ... mode in the second quarter of 2007, according to the ... hiring. , ,The report, published after former Federal Reserve ... the second half of the year, indicates that 14 percent ...
Cached Biology Technology:
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
(Date:3/23/2015)... March 23, 2015  In the 2014 fiscal year, ... conviction losses. This figure accounts for a fraction of ... The Nilson Report, exceeds $11 billion globally. The polygraph ... a crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test ...
(Date:3/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces its biometric payment ... products featured in 2015 "I Want That" International CES ... on the DIY Network.   DIY,s "I ... , site of the 2015 International CES for a ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3
... the University of Illinois have developed a new model ... transform the understanding of how plants and soils interact ... model takes into account the role of nitrogen dynamics ... change and rising atmospheric carbon dioxide. Current models ...
... (Dec. 11, 2007) A new study comparing the ... actual climate data finds that the models do an ... of the atmosphere. This research, published on-line Wednesday ... raises new concerns about the reliability of models used ...
... climate negotiations proceed in Bali, Indonesia, researchers have taken ... different countries to future climate change. The research ... Centre for Theoretical Physics in Trieste, Italy, found that ... gas-emitting nations that are currently unbound by the Kyoto ...
Cached Biology News:New model revises estimates of terrestrial carbon dioxide uptake 2New model revises estimates of terrestrial carbon dioxide uptake 3New study increases concerns about climate model reliability 2New study increases concerns about climate model reliability 3Scientists develop new measure of 'socioclimactic' risk 2Scientists develop new measure of 'socioclimactic' risk 3Scientists develop new measure of 'socioclimactic' risk 4
... The MONOLIGHT 3096 Microplate Luminometer ... chemi- and bioluminescence and for,all measurements ... microplates,i.e. for reactions where the light ... of time, as well as for ...
... new Adept CE 4100 high pressure ... flow precision, with software drive compensation, reducing ... 0.001-10mL/min are selectable in 0.001mL steps. , ... inert and bio-compatible., Pumps may be programmed ...
High affinity antibodies recognizes HSP70 protein from human cardiac tissue. Could be used for Westerb blotting application, ELISA....
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
Biology Products: